Memorial Sloan-Kettering Cancer Center

11/17/2026 | Press release | Distributed by Public on 11/17/2026 07:37

Investigational Peptide Vaccine Demonstrates Survival Benefit in People with Acute Myeloid Leukemia

New findings from a pivotal phase 3 registrational study conducted by SELLAS Life Sciences Group demonstrated that a peptide vaccine, discovered at Memorial Sloan Kettering Cancer Center (MSK), met its primary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful improvement compared with investigator's choice of best available treatment for patients with acute myeloid leukemia (AML) whose cancer had returned after treatment and who had achieved another remission. The trial's topline results, announced today, point to the potential of this treatment as a first-in-class maintenance immunotherapy, while further illustrating how scientific discoveries made inside MSK laboratories pave the way for new treatment options for patients.

In the REGAL trial, patients treated with galinpepimut-S (GPS) experienced a 41% reduction in the risk of death compared with those receiving best available treatment. Median OS was 24 months with GPS versus 14.7 months with best available treatment. Most treatment-related side effects with GPS were mild to moderate, and no new safety signals were identified.

David A. Scheinberg, MD, PhD, a leader in immunotherapy drug development along with colleagues at MSK, invented this vaccine targeting WT1, an antigen found in the cancer cells of more than 95% of people with AML (as well as in ovarian cancer, mesothelioma, and other cancers and leukemias). The vaccine uses synthetic peptides - short chains of amino acids, the building blocks of proteins - to stimulate a targeted immune response against leukemia and cancer cells. MSK licensed GPS to SELLAS in 2014 to continue clinical development. Unlike patient-specific or neoantigen vaccines, GPS is an off-the-shelf vaccine that might be used in many patients and possibly several cancers.

Dr. Scheinberg said, "Two decades of research have given us a much clearer picture of how the immune system can recognize and attack tumors and leukemias, and these insights are helping lay the groundwork for these exciting, new immune-based approaches that could safely benefit more people with cancer. These data bring us closer to having the first off-the-shelf vaccine for cancer patients."

Memorial Sloan Kettering Cancer Center (MSK) has institutional financial interests, and Dr. Scheinberg has financial interests related to SELLAS Life Sciences.

MEDIA CONTACTS:
Andrea Fassacesia
[email protected]

Courtney Nowak
[email protected]

Memorial Sloan-Kettering Cancer Center published this content on November 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 17, 2026 at 13:38 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]